Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Breast Neoplasms 5Philadelphia Chromosome 4Leukemia 4Neoplasms 3Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Hematologic Diseases 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61ribociclib 60pembrolizumab 60Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × bosutinib × Clear all
NCT00880009 2021-09-27

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Pfizer

Phase 2 Terminated
16 enrolled 6 charts
Breast

Breast Neoplasms

NCT00319254 2013-01-31

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Pfizer

Phase 2 Completed
75 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00793546 2012-11-05

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Pfizer

Phase 2 Terminated
42 enrolled 7 charts
Breast

Breast Neoplasms

NCT00759837 2009-07-16

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
27 enrolled
BreastMyeloidOther hematologic neoplasm

Breast Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00777530 2008-10-23

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
48 enrolled
BreastOther hematologic neoplasm

Breast Neoplasms, Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡